When selecting patients’ once-daily oral anticoagulant, consider both their lifestyle factors AND clinical concerns

  • Emma, 42
  • RECENTLY HOSPITALIZED: ACUTE SYMPTOMATIC PE

Emma’s lifestyle factors:

  • Busy mother, 2 jobs
  • Needs an easy dosing regimen to transition from hospital to home

Dosing changes can be DIFFICULT with busy lifestyles1:

Increases in dosing frequency and medication regimen complexity were related to poor medication adherence


Once-daily LIXIANA® (edoxaban) offers patients an easy-to-use oral anticoagulant

One tablet provides 24-hour anticoagulation2,3

The once-daily starting dose is the maintenance dose for VTE4,*

  • No scheduled high- to low-dose transition necessary4

Emma’s clinical concerns:


Height/Weight/BMI:
167.6 cm/62 kg/22.07
Comorbidities:
No comorbidities; recently quit smoking; is on an oral contraceptive; takes vitamins, calcium supplements

Bleeding is a concern with anticoagulant treatment:

Emma has heard some patients have increased bleeding and is concerned she will be one of them






Once-daily LIXIANA® (edoxaban) was superior to well-managed warfarin in reducing the risk of clinically relevant bleeding5,†

Significant 19% relative risk reduction (RRR) in clinically relevant bleeding vs well-managed warfarin in patients with VTE (HR, 0.81; 95% Cl, 0.71 to 0.94; P=0.0004 for superiority)5

  • Patients taking warfarin were in the therapeutic INR range (2.0 to 3.0) for 63.5% of time (average time in therapeutic range, according to a published clinical database, is 53.7%)5,7
The safety of LIXIANA® (edoxaban) was also established in subpopulations of VTE patients—including those with dose reductions for factors that increase the risk of bleeding.5

Only LIXIANA® (edoxaban) offers both superiority in reducing clinically
relevant bleeding
AND convenient once-daily dosing from the start.

Only LIXIANA® (edoxaban) offers both superiority in reducing clinically
relevant bleeding
AND convenient once-daily dosing from the start.

  • *

    Following initial use of parenteral anticoagulant for at least 5 days.5

  • Clinically relevant bleeding is defined as the composite of major and clinically relevant nonmajor bleeding. Clinically relevant nonmajor bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with any other discomfort such as pain, or impairment of activities of daily life.5

  • Major bleeding in nonsurgical patients was defined as6

    1. Fatal bleeding, and/or
    2. Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or
    3. Bleeding causing a fall in haemoglobin level of 20 g/L-1 (1.24 mml/L-1) or more, or leading to transfusing of 2 or more units of whole blood or red cells.